Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230334 · ClinicalTrials.gov registry record · Phase 2
Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
A Phase 2 study, sponsored by Steven E. Coutre.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00230334 is a Phase 2 study that was terminated before completion, run by Steven E. Coutre. The registered enrollment target is 5 participants.
The verdict
NCT00230334, a Phase 2 study, was terminated before completion, sponsored by Steven E. Coutre.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.
Interventions
- DRUG Gleevec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2003-06-12 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230334
The ClinicalTrials.gov registry entry for NCT00230334 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Steven E. Coutre, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gleevec is the first listed.
NCT00230334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230334 about?
NCT00230334 is a clinical study titled "Phase II Gleevec Idiopathic Hypereosinophilic Syndrome". The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.
What is the current status of trial NCT00230334?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2003-06-12. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00230334?
The interventions under investigation include: Gleevec (DRUG).
Who is sponsoring clinical trial NCT00230334?
This trial is sponsored by Steven E. Coutre, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.